Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: Bioorg Chem. 2015 Dec 10;64:59–65. doi: 10.1016/j.bioorg.2015.12.003

Synthetic Isoprenoid Analogues for the Study of Prenylated Proteins: Fluorescent Imaging and Proteomic Applications

Yen-Chih Wang 1, Mark D Distefano 1,*
PMCID: PMC4731301  NIHMSID: NIHMS746686  PMID: 26709869

Abstract

Protein prenylation is a posttranslational modification catalyzed by prenyltransferases involving the attachment of farnesyl or geranylgeranyl groups to residues near the C-termini of proteins. This irreversible covalent modification is important for membrane localization and proper signal transduction. Here, the use of isoprenoid analogues for studying prenylated proteins is reviewed. First, experiments with analogues containing small fluorophores that are alternative substrates for prenyltransferases are described. Those analogues have been useful for quantifying binding affinity and for the production of fluorescently labeled proteins. Next, the use of analogues that incorporate biotin, bioorthogonal groups or antigenic moieties is described. Such probes have been particularly useful for identifying proteins that are naturally prenylated within mammalian cells. Overall, the use of isoprenoid analogues has contributed significantly to the understanding of protein prenlation.

Keywords: bioorthogonal labeling, farnesylation, fluorescent isoprenoids, geranylgeranylation, prenylomics, protein prenylation, proteomics

Graphical Abstract

graphic file with name nihms746686u1.jpg

Introduction to protein prenylation

After a new polypeptide is synthesized, the resulting protein is frequently altered in a process called post-translational modification. Examples of this include cleavage by a protease, phosphorylation by a kinase or lipidation by a prenyltransferase. The diverse roles of post-translational modification include modulating enzymatic activity, altering protein-protein interactions or changing cellular localization. Protein modification with isoprenoids has been the focus of numerous studies since its discovery in the early 1990’s because of its connection to cancer.1 Members of the Ras superfamily proteins are normally prenylated and mutated forms of Ras, especially K-Ras, are involved in as many as 30% of all human cancers.2 Members of the protein prenyltransferase class of enzymes include protein farnesyltransferase (PFTase) and geranylgeranyltransferase I (GGTase I). These prenyltransferase enzymes are heterodimers containing a common α-subunit but different β-subunits that are only about 25% sequence identical.3 Most contacts between the substrates and the enzyme involve the β-subunit (Figure 1, Upper Panel).

Figure 1.

Figure 1

Structure of PFTase. Upper Panel: Global structure of PFTase bound to the peptide CVIM and an isoprenoid analogue. Lower Panel: Expanded view of the isoprenoid analogue bound in the active site. Color scheme: α-subunit (magenta), β-subunit (white), CVIM peptide (yellow) and isoprenoid (C: green; N: blue; O: red; P: orange). For the expanded view, both subunits are shown in gray with C-12 of the isoprenoid highlighted in cyan. The peptide substrate has been removed to highlight the isoprenoid binding pocket. These images were created using the pdb file 1D8D.4

PFTase and GGTase-I catalyze the transfer of farnesyl (C15) and geranylgeranyl (C20) groups respectively, from the corresponding allylic diphosphates. In the resulting alkylated protein, the isoprenoid group is linked to a cysteine residue within the C-terminal amino acid sequence referred to as a Ca1a2X motif where C is a cysteine, a1 and a2 are usually aliphatic amino acids and X is the major determinant for modification by either PFTase or GGTase I (Figure 2).57 It has been reported that farnesylation by PFTase occurs when X is alanine, serine, methionine or glutamine, while geranylgeranylation by GGTase I occurs when X is leucine or phenylalanine. Additional proteins are di-geranylgeranylated at their C-termini when they contain sequences including CC and CXC; these latter sequences are prenylated by protein geranylgeranyltransferase type II (GGTase-II). GGTase-II, also called RabGGTase, differs both structurally and functionally from the canonical PFTase and GGTase-I enzymes because it recognizes more extensive elements from its cognate protein substrates, Rab proteins.8 Once prenylated, the resulting proteins typically move to the endoplasmic reticulum where they may be further processed by the proteases Rce1p or Ste24p that remove the a1a2X tripeptide and methylated by a SAM-dependent methyltransferase (Icmt) to produce proteins with a C-terminal methyl ester (Figure 2).9

Figure 2.

Figure 2

C-terminal prenylation and subsequent proteolysis and methylation. The prenyl group can be a farnesyl group (C15) as shown here or a geranylgeranyl group (C20). In the latter case, prenylation is catalyzed by GGTase-I or -II in lieu of PFTase.

Protein prenylation is not only common in mammals10,11 but is also a ubiquitous post-translational modification in all eukaryotes. For example, prenylated Ras is a more potent activator of S. cerevisiae adenylyl cyclase than is the non-prenylated form.12 It has also been found that prenylation of signal transduction proteins is essential for the viability of C. albicans which is an opportunistic fungal pathogen.13 Other groups have identified prenylated proteins and confirmed their significance in P. falciparum which is the causative agent for malarial disease.14 A vast array of prenylation inhibitors have been developed to combat numerous illnesses caused by cancers, protozoan pathogens, and fungal infections.1520 Prenylation has also been found to be critical in plants.21,22 Recently, interest in prenylation has expanded to include biotechnology applications since prenyltransferases can be used to enzymatically incorporate non-natural functional groups into protein substrates.2325 The resulting modified polypeptides can be further transformed via bio-orthogonal reactions to produce a variety of useful species including PEGylated proteins,26 protein multimers27 and protein-DNA conjugates.28,29 The focus of this review is on the use of isoprenoid analogues for the study of prenylated proteins. A wide variety of synthetic isoprenoids has been prepared to probe the specificity and mechanism of prenyltransferases,30,31 serve as inhibitors,32 and study prenylation in cells;33 those topics are not covered here since a number of excellent reviews describing that work have already been published. Instead, the use of analogues containing fluorescent groups, labels for pull-down experiments and functional groups for bio-orthogonal reactions is the emphasis here since considerable progress has been made in this area in the last 10 years.34

Fluorescent analogues

Since the native isoprenoid substrates of prenylation (FPP and GGPP) do not have particularly useful spectroscopic properties, this makes the monitoring of localization of intracellular proteins and their biochemical characterization difficult. Fluorescent derivatives, prepared via chemical synthesis (Figure 3) have been used to label proteins in vitro or in live cells and have thus been particularly useful for studying the interaction and subcellular localization of prenylated proteins.

Figure 3.

Figure 3

Fluorescent analogues of FPP and GGPP used for the study of protein prenylation.

One approach to produce fluorescent FPP and GGPP analogues is to extend double bond conjugation; thus FPP analogue (ΔΔFPP, 1a, and GGPP analogue (ΔΔGGPP, 1b, were synthesized and studied.35,36 The alcohol form of 1b (ΔΔGGOH) showed blue fluorescence in methanol, with λex = 310 nm and λem = 410 nm but the fluorescence intensity at 410 nm was largely quenched in aqueous solution. Side-chain prenylation of N-acetylated Cys methyl ester with 1b showed λex = 360 nm and λex = 460 nm in Tris buffer demonstrating the environmental sensitivity of the conjugated fluorophore. Compound 1b is a substrate for yeast GGTase-I with a KM value of 0.33 μM (compared with 3.45 μM for GGPP) but the prenyl-transfer in uncorrected fluorescence units) was lower than that of GGPP. The efficiency (Vmax dissociation constant (KD) of AcCys(ΔΔGG)Me to RhoGDI, which forms a complex with geranylgeranylated Rho protein, is 15.1 μM (2.45 μM for AcCys(GG)Me) indicating that the more rigid ΔΔGG analogue manifests lower affinity for the protein target. The alcohol of 1a (ΔΔFOH) displayed blue fluorescence in methanol, with λex = 360 nm and λem = 465 nm but again the fluorescence is quenched in aqueous solution. Compound 1a is not a substrate for yeast PFTase but instead, is a potent competitive inhibitor (Table 1).

Table 1.

Summary of properties of fluorescent isoprenoid analogues used to study protein prenylation.

Compound λex (nm) λex (nm) Substrate (S) or Inhibitor (I) Peptide or protein substrate KM, KI or KD {enzyme}
FPP ND ND S DsGCVLS KM = 27 μM {yPFTase}36
DsGCVLS KM = 46 nM44, 28 nM45 or 1.5 uM46 {mPFTase}
KD = 60 nM {mGGTase-II} 38
GGPP ND ND S DsGCVLL KM = 3.45 μM {yGGTase-I}35
KD = 0.25 nM {mGGTase-I}42
KD = 8 nM {mGGTase-II}38
1a 360 465 I DsGCVLL KI = 8.8 μM {yPFTase}36
1b 310 410 S DsGCVLL KM = 0.33 μM {yGGTase-I}35
2a 340 435 S KD = 330 nM {mGGTase-II}38
2b 340 435 S KD = 49 nM {mGGTase-II}38
3 340 422 I IC50 = ~ 50 nM {mPFTase}39
5 336 460 S GFP-CVIA KM = 1.4 μM, kcat = 1.3×10−3 s−1 {mPFTase (WT)}41
GFP-CVIA KM = 0.12 μM, kcat = 0.035 s−1 {mPFTase (Y205A)}41
6a 487 550 S K-Ras KD = 1.6 nM
KM = 0.5 μM, kcat = 0.09 s−1 {mPFTase}42
6b 487 550 S RhoA KD = 6 nM, KM = 0.03 μM, kcat = 0.08 s−1 {mGGTase-I}42
Rab7 KD = 328 nM, KM = 4.7 μM, kcat = 0.04 s−1 {mGGTase-II}42
7a 490 505 I KD = 1.1 nM {mPFTase}43
I KD = 0.23 nM {mGGTase-I}43
S Rab7 KD = 245 nM; KM = 200 nM {mGGTase-II}43
7b 490 505 I KD = 4.9 nM {mPFTase}43

Beyond the above two unsaturated analogues, all of the subsequent fluorescent analogues shown in Figure 3 have been prepared by appending existing fluorophores onto the end of the isoprenoid chain placing them in the vicinity of C-12 of FPP (Figure 1, Lower Panel, C-12 colored in cyan). The first two examples of such analogues are the N-methylanthranilate-labeled FPP analogue (2a) and GGPP analogue (2b).37,38 Both compounds are characterized by λex at 340 nm and λem at 435 nm and both compounds are substrates for GGTase-II with 2b binding better than 2a (compare KD values of 330 nM and 49 nM for 2a and 2b, respectively) presumably because 2b is structurally more similar to GGPP.

The first advantage of appending a fluorophore onto the isoprenoid chain is that it facilitates the determination of binding affinity and kinetics. Previous attempts to determine those properties depended on changes in the intrinsic tryptophan fluorescence in the active site but in many cases the intensity changes were small. If an extra fluorophore is attached to the isoprenoid chain and binding of the fluorescent derivatives to the enzymes results in significant fluorescence changes, binding affinity can be measured via fluorescence titration. Subsequent affinities of non-fluorescent substrates can be determined by competitive titrations. Thus, the binding constants of 2a and 2b for GGTase-II were determined in this manner. The transient kinetics of 2a, 2b, FPP and GGPP interaction with GGTase-II were determined similarly but the signal originated from fluorescence resonance energy transfer between a protein-derived tryptophan and the N-methylanthranilate moiety present in the isoprenoid.

Although compound 2a and 2b have applicability in enzymatic assays, the ester linkage in the structure may be cleaved by nonspecific esterases in cellular experiments. A more stable anthranilate derivative with an amine linkage (3) should overcome this potential problem. Incubation of cells with compound 3 led to the accumulation of non-prenylated Ras, which can be prevented by coincubation with FPP, indicating that compound 3 is likely a competitive inhibitor with respect to FPP.39 The alcohol version of compound 3 is toxic to RPMI-8402 human leukemia cells with IC50 of ~10 nM. The fluorescent analogue 4 and its alcohol version were also visualized within cells by fluorescence microscopy but their enzymatic properties were not investigated.

Compound 5 was originally designed to study undecaprenyl pyrophosphate synthesase (UPPs) which produces C55 undecaprenyl pyrophosphate (UPP) via consecutive elongation reactions using eight IPP units with an FPP primer.40 In aqueous solution, compound 5 displays λex = 336 nm and λem = 460 nm. Due to the electron-withdrawing ability of the CF3 substituent, the lowest unoccupied molecular orbital (LUMO) is decreased compared to the CH3 counterpart resulting in a red shift of both λex and λem. Compound 5 is both an inhibitor for UPPs when FPP is present and a slow substrate for UPPs when FPP is absent. The KM of compound 5 (0.69 μM) and its KI (0.57 μM) are similar to the KM of FPP (0.40 μM) but the reaction using 5 is significantly slower compared to the reaction using FPP (kcat using 5 is 125-fold less than that obtained using FPP). Similarly, Distefano and coworkers found that compound 5 is a slow substrate for PFTase potentially because of the greater steric bulk of compound 5 relative to FPP.41 The molecular volume of 5 is approximately 25% larger than FPP. The kcat/KM value for compound 5 is more than 350-fold lower than that for FPP. However, it was shown that if the active site of PFTase was expanded by mutating Tyr at 205 to Ala, the mutant enzyme can use compound 5 much more efficiently (kcat/KM increases approximately 300-fold compared to wild-type enzyme, Table 1).

In the design of fluorescent isoprenoid analogues, the fluorophore should be small to mimic the natural substrate but the fluorescent intensity should also be high to provide maximal sensitivity. The fluorophore 7-nitro-benzo[1,2,5]oxadiazol-4-ylamino (NBD) is example that achieves a good balance between minimal size and maximal fluorescence. The FPP analogue (6a) and GGPP analogue (6b) have λex = 487 nm and λem = 550 nm.42 Addition of excess PFTase, GGTase-I or GGTase-II to a solution of 6a or 6b resulted in large fluorescent changes allowing dissociation constants of 1.6 nM, 6.0 nM and 328 nM for PFTase, GGTase-I and GGTase-II, respectively, to be determined by fluorescence titration (Table 1).

A second useful feature of appending a fluorophore onto the isoprenoid chain is that it facilitates the visualization of prenylated proteins if the isoprenoid analogue is an alternative substrate. In an in vitro prenylation assay, prenylated proteins can be resolved via SDS-PAGE and fluorescence intensity can be quantified as exemplified with 2a, 2b, 6a and 6b. If the sensitivity of the assay is high enough, steady-state kinetics can be measured as in the case of 6a and 6b (Table 1). In cell labeling experiments, in vivo conjugation can be imaged if the isoprenoid analogue is stable. Transiently expressed YFP-K-Ras and CFP-RabGDI in COS-7 cells in the presence of 6a or 6b were successfully visualized after analog incorporation using SDS-PAGE analysis; the intracellular distribution of compound 6b in human epidermal carcinoma A431 cells was also visualized via fluorescence microscopy.42

BODIPY-labeled derivatives 7a and 7b displayed large fluorescence changes upon binding to protein prenyltransferases, which allowed for the determination of their affinities using fluorescence titration experiments.43 The results showed that 7a (KD = 1.1 nM), 7b (KD = 4.9 nM), and FPP (KD = 28–46 nM) have high affinities for mPFTase and 7a (KD = 0.25 nM) and GGPP (KD = 0.23 nM) have comparable affinities for GGTase-I. However, GGTase-II displayed an affinity for 7a (KD = 245 nM) substantially lower compared to FPP (KD = 60 nM). Unfortunately among the three enzymes, only GGTase-II can utilize 7a as a substrate to prenylate its protein substrates whereas PFTase and GGTase-I could not. This highlights the problem of using larger fluorophores that sometimes results in the generation of poor substrates. Time-resolved changes in polarization of the BODIPY fluorophore were used to assay GGTase-II-mediated transfer of 7a onto Rab 7 and determine a KM of 200 nM for the isoprenoid substrate; while no kcat value was reported, the authors did note that the rate obtained for GGTase-II-catalyzed prenylation of Rab7 with 7a was comparable to that observed with 6b suggesting that the former is an efficient substrate for GGTase-II.43 Finally, compound 7a was also used to monitor its localization in baby hamster kidney (BHK) cells and in whole zebrafish, demonstrating the utility of these fluorescent compounds for imaging applications.

Probes for prenylomic analysis

Despite the fact that protein prenylation is a widespread phenomenon in eukaryotic cells that is essential for the proper function of many important signaling proteins, the total number of prenylated proteins which comprise the prenylome is still unclear. Only a fraction of predicted prenylated proteins have been experimentally confirmed, leaving the true size of the eukaryotic prenylome unknown. Prenylated proteins have been traditionally detected by metabolic labeling with radioactive substrates such as [3H]mevalonate, [3H]FPP or [3H]GGPP.47 However, this method suffers from disadvantages including low sensitivity and long exposure times necessary for detection (weeks to months). To address these limitations, chemical probes for protein prenylation have been developed to improve the detection of prenylated proteins and to allow for their selective enrichment (Figure 4); as was noted above, these analogues generally involve modification of the third isoprenoid unit proximal to C-12 of FPP (Figure 1, Lower Panel, C-12 in colored in cyan). These molecules differ from the fluorescent analogues 17 described above because they contain groups suitable either for pull-down, immunological detection, or further chemical functionalization through bioorthogonal reaction; while the fluorescent analogues discussed above are useful for labeling experiments performed with purified proteins in vitro, the fluorophores generally lack the sensitivity necessary to allow visualization of prenylated proteins in cellular extracts.

Figure 4.

Figure 4

Synthetic probes for studying the prenylome.

The biotinylated derivative 8b allowed prenylated proteins to be enriched by pull-down with streptavidin beads and subsequent analysis by Western blot and MS.48 While the affinity of compound 8b for PFTase, GGTase-I and GGTase-II is reduced compared to their native substrates it is comparable to that of the isopreniod analogues noted above. Unfortunately, compound 8b is only a substrate for wild type GGTase-II. Little or no transfer activity could be detected for PFTase and GGTase-I. While such selectivity is helpful for labeling only substrates of GGTase-II, it makes the probe less useful for examining the entire prenylome. Mutants of the PFTase (W102T_Y154T or W102T_Y154T_Y205T) and GGTase-I (F52Y_F53Y_Y126T) with expanded active sites were found to use compound 8b as a substrate allowing the detection of prenylated protein substrates. However, there are two disadvantages of using compound 8b as a probe to detect prenylated proteins. First, if PFTase or GGTase substrates are being sought, cells must be transfected to express the mutant transferase enzymes. This adds an extra complication and limits its applicability to ex vivo (cell culture) systems. Moreover, using transfected cells may not faithfully reproduce the actual physiologically relevant levels of prenyltransferases found in normal cells. Second, it is known from crystallography that in the active sites of both PFTase and GGTase-I, the protein and isoprenoid substrates physically contact each other49 so that the structure of the isoprenoid can influence the peptide specificity. Thus, the identified prenylome may not be the true native prenylome if the isoprenoid analogues differ significantly in structure relative to FPP or GGPP; this is a subtle but important pitfall. Efforts to truncate the structure to create an alternative substrate for PFTase and GGTase-I were not successful. A biotinylated derivative with shortened chain length (8a) was again transferred only by GGTase-II and was transferred less efficiently than compound 8b suggesting that shortening of the isoprenoid chain resulted in a reduction in the affinity for the enzyme.43

A solution to the above mentioned problems is to use isoprenoid analogues with smaller functional handles that are bona fide alternative substrates. After prenylation, a capture/labeling reagent can be attached via a bioorthogonal chemical reaction. The choice of ligation chemistry depends on the downstream application with the common ones being the ‘click’ reaction (also known as the Cu-catalyzed alkyne-azide cycloaddition, CuAAC reaction)50 and Staudinger reaction.51 The advantage of this strategy is that different types of chemical handles can be ligated with one kind of isoprenoid analogue. A number of such reagents including affinity labels (e.g., biotin, FLAG, etc.), reporter dyes and oligonucleotide tags are commercially available. Isoprenoids of this kind include compounds 9a, 9b, 10a, 10b, 11a and 11b. All of these analogues are substrates for PFTase.

Growth of COS cells in the presence of compound 9a or its unphosphorylated alcohol version resulted in incorporation of this azide-containing isoprenoid into proteins. Chemoselective derivatization of prenylated proteins by a Staudinger reaction was accomplished using a biotinylated phosphine capture reagent. 52 The resulting protein conjugates were specifically detected or affinity purified using streptavidin-linked horseradish peroxidase or agarose beads, respectively. Subsequent MS analysis identified 21 different farnesylated proteins including those with potentially novel farnesylation motifs. It was reported that the azide of compound 9a can isomerize between C-12 and C-10 yielding a mixture of products that can complicate analysis.53 Use of compound 9b should overcome this problem.23 Similar experiments with 9c, a geranylgeranyl diphosphate analogue allowed 10 different novel geranylgeranylated proteins to be identified including Rap2c.54 Tate and coworkers used the same analogue in conjunction with a multifunctional labeling reagent that incorporated biotin and rhodamine to successfully enrich and visualize Rab proteins.55

The rapid rate of the CuAAC reaction has made it the method of choice for many proteomic profiling protocols as an alternative to the Staudinger reaction. However, background labeling occurs in that reaction when the alkyne reagent is used in excess.56,57 Significantly lower levels of non-specific reaction occur when the azide partner is employed at high concentration. DeGraw et al. compared the labeling of prenylated proteins with TAMRA-based detection reagents in HeLa cells after metabolic labeling with either compound 10a or the alcohol form of 9a. SDS-PAGE followed by in-gel fluorescence analysis showed that incorporation using compound 10a followed by detection with TAMRA-azide gave significantly lower levels of background labeling relative to experiments employing 9a and TAMRA-alkyne.56 2-D gel electrophoresis of labeled proteins from HeLa cells grown in the presence of the unphosphorylated form of 10a followed by MS analysis allowed 7 different modified proteins to be identified. A differential gel electrophoresis-based method using 6b in which the levels of prenylated proteins in the presence and absence of a farnesylation inhibitor were compared allowed the identification of proteins whose levels both decreased (8 proteins) and increased (11 proteins) in response to the drug.58 These results are particularly noteworthy since they demonstrate how cellular physiology in response to therapeutic agents can be analyzed using these types of experiments.

Hang and coworkers have compared the labeling signals and patterns using alkyne-containing probes of varying size.57 Jurkat cells were treated with the free alcohol forms of 9a, 10a, 11a and 12a and the resulting cell lysates were conjugated via the CuAACreaction with rhodamine-azide or rhodamine-alkyne. Lysates were separated by SDS-PAGE and scanned for fluorescence. Much better labeling compared with background was obtained using 10a, 11a and 12a compared to 9a. This is consistent with other reports concerning the use of azide- versus alkyne-based probes.56 Labeling was stronger with 10a and 11b compared with 9a and 11a. In that work, 10a was chosen for subsequent experiments because its synthesis is the most straightforward and was found to be more stable compared to other alkyne-containing isoprenoid probes.57,59 Interestingly, they used 10a to show that SifA, a protein from S. typhimurium involved in bacterial replication was prenylated in HeLa cells. That result was particularly noteworthy since it suggests that the bacteria rely on host prenyltransferases to produce prenylated proteins important for bacterial replication. In a subsequent paper, they extended these results using an improved capture and release azide-based reagent to identify a large number of putative prenylated proteins and demonstrated that prenylation of the long isoform of ZAP was essential for its membrane targeting and antiviral activity.43 In addition to the azide- and alkyne-modified isoprenoid analogues described above, probes containing aldehydes,26 ketones, strained alkenes60 and multiple functional groups27 that provide additional levels of chemical orthogonality have also been prepared; these may be useful for the next generation of metabolic labeling experiments since they could allow multiple modifications to be analyzed simultaneously.

Finally, it should be noted that antibodies have proven to be useful in both the detection and immunoprecipitation of proteins with post-translational modifications. However, it was reported that antibodies produced to detect farnesylated proteins showed cross-reaction with other proteins.6163 An alternative approach to detect prenylated proteins is to produce antibodies against polypeptides modified with non-natural farnesyl analogues. In this way, it is less likely that the resulting antibodies will manifest crossreactivity. Since compound 12 is also an effective alternative substrate for PFTase, Spielman and coworkers have produced antibodies specific for the anilinogeranyl moiety.34 The alcohol version of compound 12 was incorporated into cellular proteins in a PFTase dependent manner. In a subsequent report, 2-D electrophoresis and western blotting with these antibodies allowed the detection of numerous farnesylated proteins in the proteome of leukemia cells.64

Concluding Remarks and Future Directions

The importance of protein prenylation for functional biochemical signaling has stimulated considerable interest in this post-translational modification and synthetic isoprenoid analogues have proved to be quite useful for studying this process. Compounds that incorporate fluorescent moieties have allowed the binding affinities of isoprenoids to prenylating enzymes to be quantified; they have also facilitated the preparation of fluorescently labeled forms of prenylated proteins for detection in various assays. Synthetic isoprenoid probes incorporating biotin, bio-orthogonal functional groups or antigenic moieties have allowed prenylated proteins present in cell culture to be identified; this includes known proteins as well as several previously uncharacterized ones. Despite this success, there is still considerable work to be done. While over 600 putative prenylation sequences are known in the human genome, only about 50 have been conclusively identified; methods capable of more sensitive detection are needed to address this. In addition, to date, all proteomic experiments have been performed in cell culture. These tools have yet been generally applied in tissue samples or whole animal models to study disease. Highly efficient incorporation coupled with sensitive detection will be necessary to accomplish that goal. Finally, it should be noted that the enzymatic alkylation of cysteine residues with isoprenoids is only the first step in the biogenesis of mature prenylated proteins. Additional enzymatic steps including proteolysis, methylation and fatty acid acylation are necessary in certain cases to produce fully functional proteins. Synthetic isoprenoid probes should prove to be highly useful for the study of those processes as well. Recently, simple methods have been developed for the synthesis of prenylated peptides bearing C-terminal methyl esters.65,66 This should facilitate studies of these later steps.

Highlights.

  • Protein prenylation is a common post-translational modification in eucaryotes

  • Prenylation involves the addition of farnesyl (C15) and geranylgeranyl (C20) groups

  • Fluorescent isoprenoids have facilitated the study of prenylating enzymes

  • Isoprenoids containing bioorthogonal groups have been used to identify prenylated proteins

Acknowledgments

This research was supported by the National Institutes of Health (GM084152 and CA185783) and the National Science Foundation (CHE-1308655).

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

  • 1.Bos JL. Cancer Res. 1989;49:4682. [PubMed] [Google Scholar]
  • 2.Saxena N, Lahiri SS, Hambarde S, Tripathi RP. Cancer Invest. 2008;26:948. doi: 10.1080/07357900802087275. [DOI] [PubMed] [Google Scholar]
  • 3.Lackner MR, Kindt RM, Carroll PM, Brown K, Cancilla MR, Chen C, de Silva H, Franke Y, Guan B, Heuer T, Hung T, Keegan K, Lee JM, Manne V, O’Brien C, Parry D, Perez-Villar JJ, Reddy RK, Xiao H, Zhan H, Cockett M, Plowman G, Fitzgerald K, Costa M, Ross-Macdonald P. Cancer Cell. 2005;7:325. doi: 10.1016/j.ccr.2005.03.024. [DOI] [PubMed] [Google Scholar]
  • 4.Long SB, Casey PJ, Beese LS. Structure. 8:209. doi: 10.1016/s0969-2126(00)00096-4. [DOI] [PubMed] [Google Scholar]
  • 5.Moores SL, Schaber MD, Mosser SD, Rands E, O’Hara MB, Garsky VM, Marshall MS, Pompliano DL, Gibbs JB. J Biol Chem. 1991;266:14603. [PubMed] [Google Scholar]
  • 6.Fu HW, Casey PJ. Recent Prog Horm Res. 1999;54:315. [PubMed] [Google Scholar]
  • 7.Wang YC, Dozier JK, Beese LS, Distefano MD. ACS Chem Biol. 2014;9:1726. doi: 10.1021/cb5002312. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Rak A, Pylypenko O, Niculae A, Pyatkov K, Goody RS, Alexandrov K. Cell. 2004;117:749. doi: 10.1016/j.cell.2004.05.017. [DOI] [PubMed] [Google Scholar]
  • 9.Winter-Vann AM, Casey PJ. Nat Rev Cancer. 2005;5:405. doi: 10.1038/nrc1612. [DOI] [PubMed] [Google Scholar]
  • 10.Epstein WW, Lever D, Leining LM, Bruenger E, Rilling HC. Proc Natl Acad Sci USA. 1991;88:9668. doi: 10.1073/pnas.88.21.9668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Roskoski R., Jr Biochem Biophys Res Commun. 2003;303:1. doi: 10.1016/s0006-291x(03)00323-1. [DOI] [PubMed] [Google Scholar]
  • 12.Horiuchi H, Kawata M, Katayama M, Yoshida Y, Musha T, Ando S, Takai Y. J Biol Chem. 1991;266:16981. [PubMed] [Google Scholar]
  • 13.Song JL, White TC. Microbiology. 2003;149:249. doi: 10.1099/mic.0.25887-0. [DOI] [PubMed] [Google Scholar]
  • 14.Chakrabarti* D, Azam T, DelVecchio C, Qiu L, Park Y-i, Allen CM. Mol Biochem Parasit. 1998;94:175. doi: 10.1016/s0166-6851(98)00065-6. [DOI] [PubMed] [Google Scholar]
  • 15.Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, Waldmann H. Nat Chem Biol. 2006;2:518. doi: 10.1038/nchembio818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hast MA, Fletcher S, Cummings CG, Pusateri EE, Blaskovich MA, Rivas K, Gelb MH, Van Voorhis WC, Sebti SM, Hamilton AD, Beese LS. Chem Biol. 2009;16:181. doi: 10.1016/j.chembiol.2009.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Hast MA, Nichols CB, Armstrong SM, Kelly SM, Hellinga HW, Alspaugh JA, Beese LS. J Biol Chem. 2011;286:35149. doi: 10.1074/jbc.M111.250506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sunami S, Ohkubo M, Sagara T, Ono J, Asahi S, Koito S, Morishima H. Bioorg Med Chem Lett. 2002;12:629. doi: 10.1016/s0960-894x(01)00813-7. [DOI] [PubMed] [Google Scholar]
  • 19.Berndt N, Hamilton AD, Sebti SM. Nat Rev Cancer. 2011;11:775. doi: 10.1038/nrc3151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Palsuledesai CC, Distefano MD. ACS Chem Biol. 2015;10:51. doi: 10.1021/cb500791f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Randall SK, Crowell DN. Crit Rev Biochem Mol. 1999;34:325. doi: 10.1080/10409239991209336. [DOI] [PubMed] [Google Scholar]
  • 22.Hemsley PA. New Phytol. 2015;205:476. doi: 10.1111/nph.13085. [DOI] [PubMed] [Google Scholar]
  • 23.Duckworth BP, Xu J, Taton TA, Guo A, Distefano MD. Bioconjugate Chem. 2006;17:967. doi: 10.1021/bc060125e. [DOI] [PubMed] [Google Scholar]
  • 24.Gauchet C, Labadie GR, Poulter CD. J Am Chem Soc. 2006;128:9274. doi: 10.1021/ja061131o. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Ochocki JD, Distefano MD. Med Chem Commun. 2013;4:476. doi: 10.1039/C2MD20299A. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rashidian M, Song JM, Pricer RE, Distefano MD. J Am Chem Soc. 2012;134:8455. doi: 10.1021/ja211308s. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Rashidian M, Kumarapperuma SC, Gabrielse K, Fegan A, Wagner CR, Distefano MD. J Am Chem Soc. 2013;135:16388. doi: 10.1021/ja403813b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Duckworth BP, Chen Y, Wollack JW, Sham Y, Mueller JD, Taton TA, Distefano MD. Angew Chem Int Ed. 2007;46:8819. doi: 10.1002/anie.200701942. [DOI] [PubMed] [Google Scholar]
  • 29.Yeo JE, Wickramaratne S, Khatwani S, Wang YC, Vervacke J, Distefano MD, Tretyakova NY. ACS Chem Biol. 2014;9:1860. doi: 10.1021/cb5001795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Kale TA, HS, Rose MW, Distefano MD. Curr Top Med Chem. 2003;3:1043. doi: 10.2174/1568026033452087. [DOI] [PubMed] [Google Scholar]
  • 31.Vervacke JS, WY, Distefano MD. Curr Med Chem. 2013;20:1585. doi: 10.2174/0929867311320120008. [DOI] [PubMed] [Google Scholar]
  • 32.Gibbs RAZ, TJ, Sebolt-Leopold JS. Curr Med Chem. 2001;8:1437. doi: 10.2174/0929867013372111. [DOI] [PubMed] [Google Scholar]
  • 33.Chen M, Knifley T, Subramanian T, Spielmann HP, O’Connor KL. PLoS One. 2014;9:e89892. doi: 10.1371/journal.pone.0089892. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Troutman JM, Roberts MJ, Andres DA, Spielmann HP. Bioconjugate Chem. 2005;16:1209. doi: 10.1021/bc050068+. [DOI] [PubMed] [Google Scholar]
  • 35.Liu X-h, Prestwich GD. J Am Chem Soc. 2002;124:20. doi: 10.1021/ja0119144. [DOI] [PubMed] [Google Scholar]
  • 36.Liu X-h, Prestwich GD. Bioorg Med Chem Lett. 2004;14:2137. doi: 10.1016/j.bmcl.2004.02.077. [DOI] [PubMed] [Google Scholar]
  • 37.Owen DJ, Alexandrov K, Rostkova E, Scheidig AJ, Goody RS, Waldmann H. Angew Chem Int Ed. 1999;38:509. doi: 10.1002/(SICI)1521-3773(19990215)38:4<509::AID-ANIE509>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  • 38.Thomä NH, Iakovenko A, Owen D, Scheidig AS, Waldmann H, Goody RS, Alexandrov K. Biochemistry. 2000;39:12043. doi: 10.1021/bi000835m. [DOI] [PubMed] [Google Scholar]
  • 39.Kim S, Kleckley TS, Wiemer AJ, Holstein SA, Hohl RJ, Wiemer DF. J Org Chem. 2004;69:8186. doi: 10.1021/jo049101w. [DOI] [PubMed] [Google Scholar]
  • 40.Chen APC, Chen YH, Liu HP, Li YC, Chen CT, Liang PH. J Am Chem Soc. 2002;124:15217. doi: 10.1021/ja020937v. [DOI] [PubMed] [Google Scholar]
  • 41.Dozier JK, Khatwani SL, Wollack JW, Wang YC, Schmidt-Dannert C, Distefano MD. Bioconjugate Chem. 2014;25:1203. doi: 10.1021/bc500240p. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Dursina B, Reents R, Delon C, Wu Y, Kulharia M, Thutewohl M, Veligodsky A, Kalinin A, Evstifeev V, Ciobanu D, Szedlacsek SE, Waldmann H, Goody RS, Alexandrov K. J Am Chem Soc. 2006;128:2822. doi: 10.1021/ja052196e. [DOI] [PubMed] [Google Scholar]
  • 43.Das D, Tnimov Z, Nguyen UTT, Thimmaiah G, Lo H, Abankwa D, Wu Y, Goody RS, Waldmann H, Alexandrov K. ChemBioChem. 2012;13:674. doi: 10.1002/cbic.201100733. [DOI] [PubMed] [Google Scholar]
  • 44.Chehade KAH, Kiegiel K, Isaacs RJ, Pickett JS, Bowers KE, Fierke CA, Andres DA, Spielmann HP. J Am Chem Soc. 2002;124:8206. doi: 10.1021/ja0124717. [DOI] [PubMed] [Google Scholar]
  • 45.Rawat DS, Krzysiak AJ, Gibbs RA. J Org Chem. 2008;73:1881. doi: 10.1021/jo701725b. [DOI] [PubMed] [Google Scholar]
  • 46.Subramanian T, Pais JE, Liu S, Troutman JM, Suzuki Y, Leela Subramanian K, Fierke CA, Andres DA, Spielmann HP. Biochemistry. 2012;51:8307. doi: 10.1021/bi3011362. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Maltese WA. The FASEB J. 1990;4:3319. doi: 10.1096/fasebj.4.15.2123808. [DOI] [PubMed] [Google Scholar]
  • 48.Nguyen UTT, Guo Z, Delon C, Wu Y, Deraeve C, Franzel B, Bon RS, Blankenfeldt W, Goody RS, Waldmann H, Wolters D, Alexandrov K. Nat Chem Biol. 2009;5:227. doi: 10.1038/nchembio.149. [DOI] [PubMed] [Google Scholar]
  • 49.Scott Reid T, Terry KL, Casey PJ, Beese LS. J Mol Biol. 2004;343:417. doi: 10.1016/j.jmb.2004.08.056. [DOI] [PubMed] [Google Scholar]
  • 50.Wang Q, Chan TR, Hilgraf R, Fokin VV, Sharpless KB, Finn MG. J Am Chem Soc. 2003;125:3192. doi: 10.1021/ja021381e. [DOI] [PubMed] [Google Scholar]
  • 51.Saxon E, Bertozzi CR. Science. 2000;287:2007. doi: 10.1126/science.287.5460.2007. [DOI] [PubMed] [Google Scholar]
  • 52.Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y. Proc Natl Acad Sci USA. 2004;101:12479. doi: 10.1073/pnas.0403413101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Rose MW, Rose ND, Boggs J, Lenevich S, Xu J, Barany G, Distefano MD. J Pept Res. 2005;65:529. doi: 10.1111/j.1399-3011.2005.00261.x. [DOI] [PubMed] [Google Scholar]
  • 54.Chan LN, Hart C, Guo L, Nyberg T, Davies BSJ, Fong LG, Young SG, Agnew BJ, Tamanoi F. Electrophoresis. 2009;30:3598. doi: 10.1002/elps.200900259. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Berry AFH, Heal WP, Tarafder AK, Tolmachova T, Baron RA, Seabra MC, Tate EW. ChemBioChem. 2010;11:771. doi: 10.1002/cbic.201000087. [DOI] [PubMed] [Google Scholar]
  • 56.DeGraw AJ, Palsuledesai C, Ochocki JD, Dozier JK, Lenevich S, Rashidian M, Distefano MD. Chem Biol Drug Des. 2010;76:460. doi: 10.1111/j.1747-0285.2010.01037.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Charron G, Tsou LK, Maguire W, Yount JS, Hang HC. Mol BioSyst. 2011;7:67. doi: 10.1039/c0mb00183j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 58.Palsuledesai CC, Ochocki JD, Markowski TW, Distefano MD. Mol BioSyst. 2014;10:1094. doi: 10.1039/c3mb70593e. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Charron G, Li MMH, MacDonald MR, Hang HC. Proc Natl Acad Sci USA. 2013;110:11085. doi: 10.1073/pnas.1302564110. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Wollack JW, Monson BJ, Dozier JK, Dalluge JJ, Poss K, Hilderbrand SA, Distefano MD. Chem Biol Drug Des. 2014;84:140. doi: 10.1111/cbdd.12303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Liu X-h, Suh D-Y, Call J, Prestwich GD. Bioconjugate Chem. 2004;15:270. doi: 10.1021/bc0342027. [DOI] [PubMed] [Google Scholar]
  • 62.Lin HP, Hsu SC, Wu JC, Sheen IJ, Yan BS, Syu WJ. J Gen Virol. 1999;80:91. doi: 10.1099/0022-1317-80-1-91. [DOI] [PubMed] [Google Scholar]
  • 63.Baron R, Fourcade E, Lajoie-Mazenc I, Allal C, Couderc B, Barbaras R, Favre G, Faye JC, Pradines A. Proc Natl Acad Sci USA. 2000;97:11626. doi: 10.1073/pnas.97.21.11626. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Onono FO, Morgan MA, Spielmann HP, Andres DA, Subramanian T, Ganser A, Reuter CWM. Mol Cell Proteomics. 2010;9:742. doi: 10.1074/mcp.M900597-MCP200. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Diaz-Rodriguez V, Mullen DG, Ganusova E, Becker JM, Distefano MD. Org Lett. 2012;14:5648. doi: 10.1021/ol302592v. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 66.Diaz-Rodriguez V, Ganusova E, Rappe TM, Becker JM, Distefano MD. J Org Chem. 2015;80:11266. doi: 10.1021/acs.joc.5b01376. [DOI] [PMC free article] [PubMed] [Google Scholar]

RESOURCES